JP6805272B2 - 改善されたｄダイマーアッセイ較正 - Google Patents
改善されたｄダイマーアッセイ較正 Download PDFInfo
- Publication number
- JP6805272B2 JP6805272B2 JP2018565846A JP2018565846A JP6805272B2 JP 6805272 B2 JP6805272 B2 JP 6805272B2 JP 2018565846 A JP2018565846 A JP 2018565846A JP 2018565846 A JP2018565846 A JP 2018565846A JP 6805272 B2 JP6805272 B2 JP 6805272B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- calibrator
- dimer
- assigned
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003154 D dimer Substances 0.000 title claims description 175
- 108010052295 fibrin fragment D Proteins 0.000 title claims description 173
- 238000003556 assay Methods 0.000 title claims description 42
- 238000000034 method Methods 0.000 claims description 110
- 239000011550 stock solution Substances 0.000 claims description 77
- 238000011088 calibration curve Methods 0.000 claims description 70
- 230000003287 optical effect Effects 0.000 claims description 55
- 238000001514 detection method Methods 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 239000003153 chemical reaction reagent Substances 0.000 claims description 29
- 238000010790 dilution Methods 0.000 claims description 16
- 239000012895 dilution Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 description 161
- 230000027455 binding Effects 0.000 description 18
- 239000004816 latex Substances 0.000 description 17
- 229920000126 latex Polymers 0.000 description 17
- 238000004590 computer program Methods 0.000 description 16
- 238000005259 measurement Methods 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 239000002245 particle Substances 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 206010051055 Deep vein thrombosis Diseases 0.000 description 6
- 208000010378 Pulmonary Embolism Diseases 0.000 description 6
- 206010047249 Venous thrombosis Diseases 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 208000005189 Embolism Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007820 coagulation assay Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 241001436679 Adama Species 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000013214 routine measurement Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16174523 | 2016-06-15 | ||
| EP16174523.7 | 2016-06-15 | ||
| PCT/EP2017/064500 WO2017216208A1 (en) | 2016-06-15 | 2017-06-14 | Improved d-dimer assay calibration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526039A JP2019526039A (ja) | 2019-09-12 |
| JP2019526039A5 JP2019526039A5 (enExample) | 2020-03-05 |
| JP6805272B2 true JP6805272B2 (ja) | 2020-12-23 |
Family
ID=56148156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565846A Active JP6805272B2 (ja) | 2016-06-15 | 2017-06-14 | 改善されたｄダイマーアッセイ較正 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3472624B1 (enExample) |
| JP (1) | JP6805272B2 (enExample) |
| CN (1) | CN109313204B (enExample) |
| WO (1) | WO2017216208A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119137670A (zh) * | 2022-05-04 | 2024-12-13 | 豪夫迈·罗氏有限公司 | 用于建立针对至少一种体外诊断医疗装置的计量学溯源性的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| JP2004309436A (ja) * | 2003-04-10 | 2004-11-04 | Asahi Kasei Chemicals Corp | ビスアミドの定量方法 |
| CA2475240A1 (en) * | 2004-07-20 | 2006-01-20 | Biophys, Inc. | Method and device to measure dynamic internal calibration true dose response curves |
| JP2006105838A (ja) * | 2004-10-07 | 2006-04-20 | Techno Medica Co Ltd | 標準物質入り容器、標準物質入り容器ケース及び分析装置 |
| JP4471867B2 (ja) * | 2005-02-25 | 2010-06-02 | シスメックス株式会社 | Ｄダイマー測定用標準物質 |
| DE102005028018A1 (de) | 2005-06-16 | 2006-12-21 | Dade Behring Marburg Gmbh | Verfahren zur Standardisierung von Gerinnungstesten |
| FR2922024B1 (fr) | 2007-10-04 | 2011-03-25 | Stago Diagnostica | Methode d'ajustement de la calibration de tests diagnostiques |
| JP5924950B2 (ja) * | 2012-01-20 | 2016-05-25 | シスメックス株式会社 | 試料分析装置 |
| CN102788882B (zh) * | 2012-08-17 | 2014-12-17 | 深圳市锦瑞电子有限公司 | 微量蛋白检测方法 |
| EP2811300A1 (en) * | 2013-06-07 | 2014-12-10 | Roche Diagniostics GmbH | Calibration for multi-component assays |
| EP2813839A1 (en) * | 2013-06-12 | 2014-12-17 | Roche Diagniostics GmbH | Calibration method for photometry |
-
2017
- 2017-06-14 WO PCT/EP2017/064500 patent/WO2017216208A1/en not_active Ceased
- 2017-06-14 CN CN201780037215.2A patent/CN109313204B/zh active Active
- 2017-06-14 JP JP2018565846A patent/JP6805272B2/ja active Active
- 2017-06-14 EP EP17732835.8A patent/EP3472624B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3472624A1 (en) | 2019-04-24 |
| WO2017216208A1 (en) | 2017-12-21 |
| CN109313204B (zh) | 2022-01-21 |
| CN109313204A (zh) | 2019-02-05 |
| JP2019526039A (ja) | 2019-09-12 |
| EP3472624B1 (en) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3033620B1 (en) | Method for the detection of the prozone effect of photometric assays | |
| US20160097777A1 (en) | Immunological method | |
| JP6805272B2 (ja) | 改善されたｄダイマーアッセイ較正 | |
| US11327077B2 (en) | Pretreatment method for rapid detection of HCV core antigen | |
| US9594088B2 (en) | Multiple time windows with associated calibration curves for extending the range of an assay | |
| JP2011047802A (ja) | 標的物質の濃度測定方法 | |
| US20240410881A1 (en) | Methods and systems for detecting antibodies by surface plasmon resonance | |
| KR20180135071A (ko) | 바이러스 항원의 혈청학적 탐지 방법 | |
| US20170089910A1 (en) | Methods and compositions for assaying blood levels of legumain | |
| JP2618629B2 (ja) | 特異的な免疫学的定量方法 | |
| US12320806B2 (en) | Assay for free light chains | |
| WO2025017135A1 (en) | Screening methods for antibody compositions | |
| US9140707B2 (en) | Sensors and methods for detecting diseases caused by a single point mutation | |
| WO2020203755A1 (ja) | 免疫測定試薬及び免疫測定方法 | |
| Garbergs | Extraction of therapeutic proteins from dried blood spots and their analysis on Gyrolab | |
| Class et al. | Inventors: Cecilia Bill (Uppsala, SE) Ann-Charlott Steffen (Solna, SE) Mats Inganas (Uppsala, SE) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20190125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200122 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200122 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201030 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201116 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201203 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6805272 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |